Compare
Cigna vs NeoGenomics Laboratories (CI vs NEO)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Cigna (CI) returned +13.1% and NeoGenomics Laboratories (NEO) +61.5%; so far this year the figures are +6.7% and +43.2%.
Cigna is the larger company by market value, about 35.5 times the size of NeoGenomics Laboratories.
Revenue grew +6.8% at CI and +11.1% at NEO over the last year.
CI yields 2.11%. NEO pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| CI | NEO | |
|---|---|---|
| Price | $293.59 | $16.84 |
| 1-day | -2.62% | +2.12% |
| YTD | +6.67% | +43.20% |
| 1 year | +13.10% | +61.46% |
| 3 years | -5.11% | +22.29% |
| Market cap | $77.4B | $2.2B |
| P/E | 12.9 | — |
| P/S | 0.27 | 2.77 |
| P/B | 1.78 | 2.72 |
| Revenue growth | +6.80% | +11.10% |
| EPS growth | +0.30% | — |
| Gross margin % | 20.7 | 44.8 |
| Net margin % | 2.1 | -4.1 |
| ROE % | 13.8 | -4.0 |
| Debt / equity | 0.72 | 0.47 |
| FCF yield % | 12.2 | -1.3 |
| Dividend yield % | 2.11 | — |
| Beta | 0.08 | 1.08 |
| RSI (14) | 49.6 | 47.7 |
| Technical rating |